Edition:
United Kingdom

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

1.51USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
29,161
52-wk High
$4.83
52-wk Low
$1.29

Select another date:

Tue, Nov 14 2017

BRIEF-Cardiome Q3 loss per share $0.20

* Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S

BRIEF-Cardiome Pharma commercially launches Xydalba in Sweden, Finland and Republic Of Ireland​

* Cardiome Pharma - has initiated commercial launch of Xydalba (dalbavancin hydrochloride) in Sweden, Finland and Republic Of Ireland​ Source text for Eikon: Further company coverage:

BRIEF-Cardiome announces agreement with Basilea

* Cardiome announces agreement with Basilea for distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel

BRIEF-Basilea says distribution agreement with Cardiome

* BASILEA ANNOUNCES DISTRIBUTION AGREEMENT WITH CARDIOME TO COMMERCIALIZE ANTIBIOTIC ZEVTERA/MABELIO (CEFTOBIPROLE) IN EUROPE AND ISRAEL

BRIEF-Cardiome provides U.S. regulatory update for BRINAVESS

* Cardiome Pharma Corp - ‍FDA advised Cardiome that data package proposed by Cardiome would not be sufficient to support a resubmission of BRINAVESS NDA​

BRIEF-Cardiome Pharma reports quarterly loss per share $0.26

* Q2 earnings per share view $-0.17, revenue view $7.1 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Cardiome Pharma Q2 loss per share $0.26

* Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Cardiome Pharma announces Health Canada approval of AGGRASTAT high dose bolus regimen

* Cardiome announces Health Canada approval of Aggrastat high dose bolus regimen

BRIEF-Cardiome's partner SteadyMed submits U.S. new drug application for TREVYENT

* Cardiome's partner steadymed submits u.s. New drug application for trevyent® for the treatment of pulmonary arterial hypertension

BRIEF-Cardiome announces licensing agreement for xydalba to support planned commercialization in Israel

* Cardiome announces licensing agreement for xydalba™ (dalbavancin hydrochloride) to support planned commercialization in Israel

Select another date: